Literature DB >> 24949661

Long term exendin-4 treatment reduces food intake and body weight and alters expression of brain homeostatic and reward markers.

Yan Yang1, Alexander A Moghadam, Zachary A Cordner, Nu-Chu Liang, Timothy H Moran.   

Abstract

Repeated administration of the long-acting glucagon-like peptide 1 receptor agonist exendin-4 (EX-4) has been shown to reduce food intake and body weight and do so without a rebound increase in food intake after treatment termination. The current study examines the neural mechanisms underlying these actions. After 6 weeks of maintenance on a standard chow or a high-fat (HF) diet, male Sprague Dawley rats were treated with EX-4 (3.2 μg/kg, i.p., twice a day) or vehicle for 9 consecutive days. Food intake and body weight (BW) were monitored daily. Expression of the genes for the hypothalamic arcuate nucleus (ARC) peptides proopiomelanocortin (POMC), neuropeptide Y (NPY), and agouti gene-related protein was determined. Expression of the dopamine precursor tyrosine hydroxylase (TH) gene in the ventral tegmental area and genes for dopamine receptors 1 (D1R) and dopamine receptor 2 in the nucleus accumbens were also determined. Pair-fed groups were included to control for the effects of reduced food intake and BW. Treatment with EX-4 significantly decreased food intake and BW over the 9-day period in both the standard chow and HF groups. HF feeding decreased POMC without changing NPY/agouti gene-related protein gene expression in the ARC. Treatment with EX-4 increased POMC and decreased NPY expression independent of the reduction of food intake and BW. Mesolimbic TH and D1R gene expression were decreased significantly in chronic HF diet-fed rats, and these changes were reversed in both EX-4 and pair-fed conditions. These results suggest a role for increased POMC and decreased NPY expression in the ARC in the effects of EX-4 on food intake and BW. Our findings also suggest that EX-4 induced the recovery of mesolimbic TH and D1R expression in HF diet-fed rats may be secondary to HF intake reduction and/or weight loss.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24949661      PMCID: PMC4138563          DOI: 10.1210/en.2014-1052

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  63 in total

1.  Hypothalamic neuropeptide expression following chronic food restriction in sedentary and wheel-running rats.

Authors:  C E de Rijke; J J G Hillebrand; L A W Verhagen; T A P Roeling; R A H Adan
Journal:  J Mol Endocrinol       Date:  2005-10       Impact factor: 5.098

2.  Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats.

Authors:  Matthew R Hayes; Scott E Kanoski; Amber L Alhadeff; Harvey J Grill
Journal:  Obesity (Silver Spring)       Date:  2011-03-17       Impact factor: 5.002

3.  Peripheral ghrelin stimulates feeding behavior and positive energy balance in a sciurid hibernator.

Authors:  Jessica E Healy; Jenna L Bateman; Cara E Ostrom; Gregory L Florant
Journal:  Horm Behav       Date:  2011-02-17       Impact factor: 3.587

4.  Altered expression of hypothalamic neuropeptide mRNAs in food-restricted and food-deprived rats.

Authors:  L S Brady; M A Smith; P W Gold; M Herkenham
Journal:  Neuroendocrinology       Date:  1990-11       Impact factor: 4.914

5.  Glucagon-like peptide (GLP-1) is involved in the central modulation of fecal output in rats.

Authors:  M A Gülpinar; A Bozkurt; T Coşkun; N B Ulusoy; B C Yegen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2000-06       Impact factor: 4.052

6.  Insulin, glucose, and pancreatic polypeptide responses to a test meal in restricting type anorexia nervosa before and after weight restoration.

Authors:  Kimberly P Kinzig; Janelle W Coughlin; Graham W Redgrave; Timothy H Moran; Angela S Guarda
Journal:  Am J Physiol Endocrinol Metab       Date:  2007-01-30       Impact factor: 4.310

7.  High-fat diet decreases tyrosine hydroxylase mRNA expression irrespective of obesity susceptibility in mice.

Authors:  Yulin Li; Timothy South; Mei Han; Jiezhong Chen; Rui Wang; Xu-Feng Huang
Journal:  Brain Res       Date:  2009-03-11       Impact factor: 3.252

8.  Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.

Authors:  Laurie L Baggio; Qingling Huang; Theodore J Brown; Daniel J Drucker
Journal:  Gastroenterology       Date:  2004-08       Impact factor: 22.682

9.  Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling.

Authors:  Sarah H Lockie; Kristy M Heppner; Nilika Chaudhary; Joseph R Chabenne; Donald A Morgan; Christelle Veyrat-Durebex; Gayathri Ananthakrishnan; Françoise Rohner-Jeanrenaud; Daniel J Drucker; Richard DiMarchi; Kamal Rahmouni; Brian J Oldfield; Matthias H Tschöp; Diego Perez-Tilve
Journal:  Diabetes       Date:  2012-08-28       Impact factor: 9.461

10.  Maternal high-fat diet during gestation or suckling differentially affects offspring leptin sensitivity and obesity.

Authors:  Bo Sun; Ryan H Purcell; Chantelle E Terrillion; Jianqun Yan; Timothy H Moran; Kellie L K Tamashiro
Journal:  Diabetes       Date:  2012-06-29       Impact factor: 9.461

View more
  13 in total

Review 1.  Regulation of energy balance by a gut-brain axis and involvement of the gut microbiota.

Authors:  Paige V Bauer; Sophie C Hamr; Frank A Duca
Journal:  Cell Mol Life Sci       Date:  2015-11-05       Impact factor: 9.261

Review 2.  Hyperpalatability and the Generation of Obesity: Roles of Environment, Stress Exposure and Individual Difference.

Authors:  Sarah-Jane Leigh; Frances Lee; Margaret J Morris
Journal:  Curr Obes Rep       Date:  2018-03

3.  Dorsomedial hypothalamic NPY affects cholecystokinin-induced satiety via modulation of brain stem catecholamine neuronal signaling.

Authors:  Claire B de La Serre; Yonwook J Kim; Timothy H Moran; Sheng Bi
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-08-17       Impact factor: 3.619

4.  Administration of Exendin-4 but not CCK alters lick responses and trial initiation to sucrose and intralipid during brief-access tests.

Authors:  Yada Treesukosol; Timothy H Moran
Journal:  Chem Senses       Date:  2022-01-01       Impact factor: 3.160

5.  Expression of glucagon-like peptide 1 receptor in neuropeptide Y neurons of the arcuate nucleus in mice.

Authors:  Yvette Ruska; Anett Szilvásy-Szabó; Dóra Kővári; Andrea Kádár; Lilla Mácsai; Richárd Sinkó; Erik Hrabovszky; Balázs Gereben; Csaba Fekete
Journal:  Brain Struct Funct       Date:  2021-10-01       Impact factor: 3.270

6.  The GLP-1 agonist exendin-4 attenuates self-administration of sweetened fat on fixed and progressive ratio schedules of reinforcement in rats.

Authors:  Kimberly A Bernosky-Smith; David B Stanger; Alexandria J Trujillo; Luke R Mitchell; Rodrigo A España; Caroline E Bass
Journal:  Pharmacol Biochem Behav       Date:  2015-12-15       Impact factor: 3.533

7.  Exendin-4 antagonizes the metabolic action of acylated ghrelinergic signaling in the hypothalamic paraventricular nucleus.

Authors:  Shayan Abtahi; Erin Howell; Jack T Salvucci; Joshua M R Bastacky; David P Dunn; Paul J Currie
Journal:  Gen Comp Endocrinol       Date:  2018-10-15       Impact factor: 2.822

8.  Increased food intake with oxyntomodulin analogues.

Authors:  Samantha L Price; James S Minnion; Stephen R Bloom
Journal:  Peptides       Date:  2015-09-30       Impact factor: 3.750

9.  Limiting glucocorticoid secretion increases the anorexigenic property of Exendin-4.

Authors:  Shin J Lee; Katharina Diener; Sharon Kaufman; Jean-Philippe Krieger; Klaus G Pettersen; Nino Jejelava; Myrtha Arnold; Alan G Watts; Wolfgang Langhans
Journal:  Mol Metab       Date:  2016-05-04       Impact factor: 7.422

Review 10.  Can We Selectively Reduce Appetite for Energy-Dense Foods? An Overview of Pharmacological Strategies for Modification of Food Preference Behavior.

Authors:  Ewa Bojanowska; Joanna Ciosek
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.